Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Ann Arbor, Michigan 48109


Purpose:

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Curcumin may be effective in preventing the development of colon cancer. PURPOSE: Phase I trial to determine the dose amount of curcumin that can be tolerated to help in preventing colon cancer in healthy men and women.


Study summary:

OBJECTIVES: - Determine the maximum tolerated dose (MTD) of curcumin as a chemopreventive agent of colon cancer in healthy subjects. - Determine if tolerable doses of this agent in uniformly milled formulation capsules are bioavailable in these subjects. - Determine the pharmacokinetics of this agent and two metabolites at the MTD and next lower escalated dose in these subjects. OUTLINE: This is a dose escalation study followed by a pharmacokinetic study. Patients receive a single oral dose of curcumin followed by a standard fatty meal. Cohorts of 3-6 patients receive escalating doses of curcumin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicities. Once the MTD is determined, additional patients are accrued to receive curcumin in the pharmacokinetic phase of the study. Patients are followed at 24, 36, 48, and 72 hours. PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for the dose escalation phase and then 12 additional patients will be accrued for the pharmacokinetic phase of this study within 3 months.


Criteria:

DISEASE CHARACTERISTICS: - Healthy men and women age 18 and over PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - WBC greater than 4,000/mm3 - Hemoglobin greater than 12 g/dL - Platelet count greater than 120,000/mm3 Hepatic: - ALT/AST less than 1.5 times upper limit of normal (ULN) - Alkaline phosphatase less than 1.5 times ULN - Bilirubin less than 1.5 mg/dL Renal: - Creatinine less than 1.7 mg/dL Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No prior cancer except surgically resected basal cell or squamous cell skin cancer - No history of peptic ulcer disease, gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin secreting tumors - No history of unreliability or noncompliance (missing pretreatment appointment more than twice) PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Not specified Endocrine therapy: - At least 14 days since prior steroids Radiotherapy: - Not specified Surgery: - Not specified Other: - At least 14 days since prior curcumin (turmeric) rich foods - At least 14 days since prior nonsteroidal antiinflammatory drugs (NSAIDs) - No chronic medications (i.e., daily for more than 28 days) except for oral contraceptives - No concurrent coumadin or other anticoagulants


NCT ID:

NCT00027495


Primary Contact:

Study Chair
Dean E. Brenner, MD
University of Michigan Cancer Center


Backup Contact:

N/A


Location Contact:

Ann Arbor, Michigan 48109
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.